Engimmune Therapeutics AG (Engimmune), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has completed a CHF15.5 million (EUR15.2m) seed financing round, co-led by Pureos Bioventures and Novo Holdings.
Engimmune is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment. By combining genome editing, functional screening, deep sequencing and machine learning, Engimmune addresses major efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapies. Engimmune’s lead products are focused on oncology, with potential to expand to autoimmune diseases in the future.
Engimmune is a spinout from the lab of Prof Sai Reddy at ETH Zurich and Dr Rodrigo Vazquez-Lombardi, co-inventor of the company’s platform technologies, who is now its Chief Scientific Officer.
Proceeds from the financing will be used to further build Engimmune’s pipeline, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
The Company also announces the appointment of TCR pioneer and industry veteran Dr Bent Jakobsen as Chairman of the Board.
